RTW Investments has significantly increased its stake in Cogent Biosciences (COGT), acquiring 4,124,755 shares valued at approximately $115.95 million, as disclosed in its February 17, 2026, SEC filing. This move raises RTW’s ownership in Cogent to 2.7% of its total assets under management, reflecting a strong conviction in the company’s growth potential, particularly as it advances its lead candidate, CGT9486, aimed at treating systemic mastocytosis and gastrointestinal stromal tumors.
The investment comes at a time when Cogent shares have surged 360% over the past year, outpacing the S&P 500’s 15% gain. With a robust balance sheet of around $900 million, Cogent is well-positioned to navigate its clinical trials and regulatory approvals, including an FDA application with a decision expected by late 2026. This strategic buy signals RTW’s belief that Cogent is transitioning from a speculative biotech to a company with tangible commercial prospects.
For market professionals, RTW’s increased stake highlights the potential for significant returns in biotech, particularly as clinical milestones approach. Investors should monitor upcoming regulatory decisions closely, as they could validate the stock’s impressive rise and further influence market sentiment.
Source: fool.com